Image source: The Motley Fool. Management attributed revenue softness to supply constraints in consumables, not demand weakness, and indicated expected recovery as manufacturing delays are resolved.

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2026.

Q1 2026 Management View "As announced last week, I'm stepping in as Interim CEO and will maintain my role as Chairman." (Chairman & Interim CEO Albert Luderer) "I would like to thank Erik for his ...

Bionano Genomics, Inc. (BNGO) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to a loss of $1.15 per share a year ago. These ...

Bionano Genomics, Inc. beats earnings expectations. Reported EPS is $-1.59292, expectations were $-1.81. Operator: Good day, and welcome to the Bionano Third Quarter 2025 Earnings Conference Call.

SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today reported certain unaudited preliminary financial results and commercial highlights for the fourth quarter and ...

Welcome to the H.C. Wainwright 27th Annual Global Investment Conference. I'm Dr. Katherine Degen, an associate biotech research analyst at the firm. I'd like to take a moment to welcome Erik Holmlin ...

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 13, 2026, at 4:30 p.m. Eastern Time to report financial results for the ...